106 related articles for article (PubMed ID: 9819125)
1. Immunodetection and characterisation of soluble CD105-TGFbeta complexes.
Li CG; Wilson PB; Bernabeu C; Raab U; Wang JM; Kumar S
J Immunol Methods; 1998 Sep; 218(1-2):85-93. PubMed ID: 9819125
[TBL] [Abstract][Full Text] [Related]
2. The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease.
Li CG; Bethell H; Wilson PB; Bhatnagar D; Walker MG; Kumar S
Atherosclerosis; 2000 Sep; 152(1):249-56. PubMed ID: 10996361
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.
Li C; Guo B; Wilson PB; Stewart A; Byrne G; Bundred N; Kumar S
Int J Cancer; 2000 Mar; 89(2):122-6. PubMed ID: 10754488
[TBL] [Abstract][Full Text] [Related]
4. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
[TBL] [Abstract][Full Text] [Related]
5. Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer.
Li C; Wang J; Wilson PB; Kumar P; Levine E; Hunter RD; Kumar S
Int J Cancer; 1998 Oct; 79(5):455-9. PubMed ID: 9761112
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105.
Li C; Guo B; Bernabeu C; Kumar S
Microsc Res Tech; 2001 Feb; 52(4):437-49. PubMed ID: 11170303
[TBL] [Abstract][Full Text] [Related]
7. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis.
Li C; Wilson PB; Levine E; Barber J; Stewart AL; Kumar S
Int J Cancer; 1999 Apr; 84(2):155-9. PubMed ID: 10096248
[TBL] [Abstract][Full Text] [Related]
8. Plasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia.
Al-Mowallad A; Carr T; Al-Qouzi A; Li C; Byers R; Kumar S
Anticancer Res; 2006; 26(1B):543-7. PubMed ID: 16739317
[TBL] [Abstract][Full Text] [Related]
9. Endoglin is expressed on human chondrocytes and forms a heteromeric complex with betaglycan in a ligand and type II TGFbeta receptor independent manner.
Parker WL; Goldring MB; Philip A
J Bone Miner Res; 2003 Feb; 18(2):289-302. PubMed ID: 12568406
[TBL] [Abstract][Full Text] [Related]
10. Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target.
Costello B; Li C; Duff S; Butterworth D; Khan A; Perkins M; Owens S; Al-Mowallad AF; O'Dwyer S; Kumar S
Int J Cancer; 2004 Apr; 109(3):436-41. PubMed ID: 14961584
[TBL] [Abstract][Full Text] [Related]
11. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells.
Li C; Hampson IN; Hampson L; Kumar P; Bernabeu C; Kumar S
FASEB J; 2000 Jan; 14(1):55-64. PubMed ID: 10627280
[TBL] [Abstract][Full Text] [Related]
12. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).
Nettelbeck DM; Miller DW; Jérôme V; Zuzarte M; Watkins SJ; Hawkins RE; Müller R; Kontermann RE
Mol Ther; 2001 Jun; 3(6):882-91. PubMed ID: 11407902
[TBL] [Abstract][Full Text] [Related]
13. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
[TBL] [Abstract][Full Text] [Related]
15. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma.
Altomonte M; Montagner R; Fonsatti E; Colizzi F; Cattarossi I; Brasoveanu LI; Nicotra MR; Cattelan A; Natali PG; Maio M
Br J Cancer; 1996 Nov; 74(10):1586-91. PubMed ID: 8932339
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-betas and CD105 expression in calcification and bone formation in human atherosclerotic lesions.
Jeziorska M
Z Kardiol; 2001; 90 Suppl 3():23-6. PubMed ID: 11374028
[TBL] [Abstract][Full Text] [Related]
17. Differential kinetics of plasma CD105 and transforming growth factor beta expression early in human acute pancreatitis.
Jamdar S; Al-Mowallad AF; Kumar S; Siriwardena AK
Pancreas; 2006 Mar; 32(2):152-8. PubMed ID: 16552334
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
19. Differential levels of soluble endoglin (CD105) in myeloid malignancies.
Calabrò L; Fonsatti E; Bellomo G; Alonci A; Colizzi F; Sigalotti L; Altomonte M; Musolino C; Maio M
J Cell Physiol; 2003 Feb; 194(2):171-5. PubMed ID: 12494455
[TBL] [Abstract][Full Text] [Related]
20. CD105 (endoglin) expression on hematopoietic stem/progenitor cells.
Pierelli L; Bonanno G; Rutella S; Marone M; Scambia G; Leone G
Leuk Lymphoma; 2001; 42(6):1195-206. PubMed ID: 11911400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
